BC Innovations | Mar 13, 2019
Distillery Therapeutics

A PYY-IgG conjugate for obesity

DISEASE CATEGORY: Endocrine/Metabolic INDICATION: Obesity Mouse and non-human primate studies suggest a PYY-IgG conjugate could help treat obesity. The fusion protein consists of a 33-amino acid PYY fragment that promotes satiation linked to an IgG...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BC Innovations | Jul 13, 2017
Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
BioCentury | Mar 25, 2017
Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
BC Innovations | Jan 9, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Neuropeptide Y receptor Y2 (NPY2R); peptide tyrosine-tyrosine (PYY) Mouse studies suggest PYY delivered as an oral spray could help suppress appetite and treat...
BC Week In Review | Jan 16, 2012
Clinical News

LX4211 tablet: Phase I data

Top-line data from a triple-crossover, U.S. Phase I trial in 18 patients showed that 400 mg oral LX4211 plus 100 mg oral Januvia sitagliptin decreased PPG vs. Januvia alone (p=0.012). The combination also increased active...
BC Week In Review | Sep 26, 2011
Clinical News

EndoBarrier Gastrointestinal Liner endocrine/metabolic data

Data from 17 obese patients with Type II diabetes showed that EndoBarrier Gastrointestinal Liner significantly reduced mean HbA1c at week 24 by 1.4% from 8.4% at baseline (p<0.01), with an excess mean weight loss of...
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
BC Week In Review | Jan 10, 2011
Clinical News

LX4211 tablet: Phase I data

A Phase I trial in 12 patients showed that 2 doses of 150 mg solid oral LX4211 significantly increased total glucagon-like peptide-1 (GLP-1) , active GLP-1 and peptide YY (PYY) from baseline (p=0.001, p=0.032 and p=0.004,...
Items per page:
1 - 10 of 44